ComplianceOnline

Weight Loss Pill from Orexigen under FDA Scrutiny

  • Date: December 08, 2010
  • Source: Admin
Webinar All Access Pass Subscription Abstract:

For decades now, doctors and health care providers have been eagerly awaiting safe and efficient weight-loss therapies. Numerous drugs have been launched so far and rejected by the FDA as they failed to meet the agency's criteria. Qnexa from Vivus Inc., and lorcaserin from Arena Pharmaceuticals Inc., are among the list of drugs that failed to gain FDA approval in recent times. Drug trials linked these drugs to potential heart problems, birth defects and cancerous tumors. Earlier this year, Meridia weight loss pill from the Abbott Laboratories stable was also recalled from the market after regulators said it increased the risk of heart attack and stroke.

Bookmark and Share

Trending Compliance Trainings

HVAC and GMP Environmental Control - for Pharmaceutical Cleanrooms
By - Roger Cowan
On Demand Access Anytime
Extractables and Leachables in Early Phase Development
By - Wayland Rushing
On Demand Access Anytime
CGMP controlled Raw Materials
By - Charity Ogunsanya
On Demand Access Anytime
OTC Drug Regulations
By - Loren Gelber
On Demand Access Anytime
Veterinary Feed Directive (VFD) Final Rule - What you need to know
By - Bernadette Alisantosa
On Demand Access Anytime
Best Sellers
You Recently Viewed
    Loading